Literature DB >> 15170601

RNA and DNA aptamers in cytomics analysis.

Henning Ulrich1, Antonio Henrique B Martins, João Bosco Pesquero.   

Abstract

BACKGROUND: The systematic evolution of ligands by exponential enrichment (SELEX) technique is a combinatorial library approach in which DNA or RNA molecules (aptamers) are selected by their ability to bind their protein targets with high affinity and specificity, comparable to that of monoclonal antibodies. In contrast to antibodies conventionally selected in animals, aptamers are generated by an in vitro selection process, and can be directed against almost every target, including antigens like toxins or nonimmunogenic targets, against which conventional antibodies cannot be raised.
METHODS: Aptamers are ideal candidates for cytomics, as they can be attached to fluorescent reporters or nanoparticles in order to study biological function by fluorescence microscopy, by flow cytometry, or to quantify the concentration of their target in biological fluids or cells using ELISA, RIA, and Western blot assays.
RESULTS: We demonstrate the in vitro selection of anti-kinin B1 receptor aptamers that could be used to determine B1 receptor expression during inflammation processes. These aptamers specifically recognize their target in a Northern-Western blot assay, and bind to their target protein whenever they are exposed in the membrane.
CONCLUSIONS: Currently, aptamers are linked to fluorescent reporters. We discuss here the present status and future directions concerning the use of the SELEX technique in cytomics. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15170601     DOI: 10.1002/cyto.a.20056

Source DB:  PubMed          Journal:  Cytometry A        ISSN: 1552-4922            Impact factor:   4.355


  18 in total

Review 1.  Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents.

Authors:  Khaled S Allemailem; Ahmad Almatroudi; Mohammed A Alsahli; Ghaiyda Talal Basfar; Faris Alrumaihi; Arshad Husain Rahmani; Amjad Ali Khan
Journal:  3 Biotech       Date:  2020-11-24       Impact factor: 2.406

2.  Cytomics emerging from cytometry.

Authors:  A Tárnok; G Brockhoff
Journal:  Cell Prolif       Date:  2006-10       Impact factor: 6.831

3.  Safety evaluation of intravenously administered mono-thioated aptamer against E-selectin in mice.

Authors:  Shin-Ae Kang; Bilegtsaikhan Tsolmon; Aman P Mann; Wei Zheng; Lichao Zhao; Yan Daniel Zhao; David E Volk; Ganesh L-R Lokesh; Lynsie Morris; Vineet Gupta; Wajeeha Razaq; Hallgeir Rui; K Stephen Suh; David G Gorenstein; Takemi Tanaka
Journal:  Toxicol Appl Pharmacol       Date:  2015-06-03       Impact factor: 4.219

4.  In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells.

Authors:  Mee Young Kim; Sunjoo Jeong
Journal:  Nucleic Acid Ther       Date:  2011-06       Impact factor: 5.486

Review 5.  Cytomics - importance of multimodal analysis of cell function and proliferation in oncology.

Authors:  A Tárnok; J Bocsi; G Brockhoff
Journal:  Cell Prolif       Date:  2006-12       Impact factor: 6.831

Review 6.  Aptamers and the next generation of diagnostic reagents.

Authors:  Varatharasa Thiviyanathan; David G Gorenstein
Journal:  Proteomics Clin Appl       Date:  2012-12       Impact factor: 3.494

7.  Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells.

Authors:  Peng Zhang; Nianxi Zhao; Zihua Zeng; Yongdong Feng; Ching-Hsuan Tung; Chung-Che Chang; Youli Zu
Journal:  Lab Invest       Date:  2009-10-12       Impact factor: 5.662

8.  RNA based antagonist of NMDA receptors.

Authors:  Garam Lee; David M MacLean; Henning Ulrich; Xiurong Zhao; Jaroslaw Aronowski; Vasanthi Jayaraman
Journal:  ACS Chem Neurosci       Date:  2014-04-16       Impact factor: 4.418

Review 9.  Aptamers: novel molecules as diagnostic markers in bacterial and viral infections?

Authors:  Flávia M Zimbres; Attila Tárnok; Henning Ulrich; Carsten Wrenger
Journal:  Biomed Res Int       Date:  2013-09-05       Impact factor: 3.411

10.  Delivery systems for in vivo use of nucleic Acid drugs.

Authors:  R R Resende; H A M Torres; K K Yuahasi; Majumder P; Ulrich H
Journal:  Drug Target Insights       Date:  2007-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.